Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
177Lu-PRRT
- Development stage
- Unknown
- Lead developer
- Advanced Accelerator Applications
- Modality
- Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
177Lu-PRRT (Lutetium-177 Peptide Receptor Radionuclide Therapy) is a targeted radiopharmaceutical therapy primarily used for the treatment of somatostatin receptor (SSTR)-positive neuroendocrine tumors (NETs). The therapy involves a radioactive isotope, Lutetium-177, conjugated to a somatostatin analog peptide (such as DOTATATE or DOTATOC) that binds with high affinity to SSTRs overexpressed on tumor cells. Upon binding, the radiopharmaceutical is internalized, and the Lutetium-177 emits beta radiation, which causes localized DNA damage and cell death within the tumor while minimizing radiation exposure to healthy tissues. It is an established systemic treatment for metastatic or inoperable NETs, with the most prominent commercial version being Lutathera (lutetium Lu 177 dotatate).
- Brand names
- Lutathera
- Other names
- 177Lu-DOTATATE177Lu-DOTATOCLutetium-177 peptide receptor radionuclide therapyLutetium177 peptide receptor radionuclide therapyLutetium 177 peptide receptor radionuclide therapy177Lu-DOTA-TATE177Lu-DOTA-TOC
02
Targets
SSTR2 (Somatostatin receptor type 2)SSTR3 (Somatostatin receptor 3)SSTR5 (Somatostatin receptor 5)
Beyond the preview
Go deeper on 177Lu-PRRT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 177Lu-PRRT.